Executive Summary
Self-expanding TAVR platforms remain a pacemaker liability, with the multicenter CONNAVIPRO registry (N=880) showing a 23.2% 30-day permanent pacemaker rate for Abbott's Navitor versus 17.6% for Medtronic's Evolut PRO+ (adjusted OR 1.53, p=0.018) — a gap that reopens the durability-versus-conduction-cost debate ESC 2025 largely papered over when it lowered the TAVI-preferred age to 70. On the elderly-mitral side, a Future Cardiology review reaffirms M-TEER's 2-3% 30-day mortality in patients ≥75 while pegging transapical TMVR mortality at 29% at one year — mitral replacement remains nowhere near a surgical substitute. St. Joseph's Health added the EVOQUE tricuspid replacement system, extending the community-hospital footprint of a technology ESC 2025 rates Class IIa but ACC/AHA 2020 doesn't address at all. The through-line: today's data tightens the case for individualized valve-and-approach selection, not platform triumphalism.
- Navitor delivered lower moderate+ PVL (2.8% vs 7.7%) than Evolut PRO+ but at the cost of a 6-point PPI penalty — a real trade-off for anyone under 75 (CONNAVIPRO, N=880).
- Snare-assisted transseptal antegrade TAVR salvaged a porcelain-aorta / severe-PAD patient with a 29mm SAPIEN 3 Ultra RESILIA — access anatomy still drives real decisions (JACC Case Reports).
- Right mini-thoracotomy transaortic TAVR (N=73) matched transfemoral for 2-year survival and MACCE despite higher comorbidity burden (ICVTS, single-center, retrospective).
- An Apple Watch AI-ECG algorithm hit AUROC 0.841 for severe structural heart disease (N=596, 30 severe cases), cutting number-needed-to-test by >60% (WATCH-SHD, medRxiv preprint).
- Deutsche Bank disclosed a $516.55M Edwards Lifesciences position, part of a broader institutional bid as EW pushed toward the top of its 6-month range.
What to watch: Medtronic's fiscal Q1 earnings on September 1 will be the first read on whether Evolut's PPI edge over Navitor is translating into real share gains against Edwards' SAPIEN franchise.
Aortic Valve (TAVR/TAVI)
Self-expanding valves still can't shake the pacemaker problem, and the two market leaders trade it differently. CONNAVIPRO — international, multicenter, retrospective, N=880 pacemaker-naïve patients treated May 2022 through December 2024 — pitted Evolut PRO+ (n=451) directly against Abbott's Navitor (n=429). After inverse-probability weighting, Navitor carried a 23.2% 30-day PPI rate versus 17.6% for Evolut PRO+ (OR 1.53, 95% CI 1.08-2.17). Navitor produced lower moderate+ paravalvular leak (2.8% vs 7.7%, p<0.001) but slightly higher mean gradients (8 vs 7 mmHg). Retrospective, non-randomized, and industry-relevant — this is hypothesis-generating, not verdict-delivering. A 5.6-point absolute PPI difference matters when ESC 2025 has made TAVI the preferred strategy at age ≥70 with tricuspid anatomy; ACC/AHA 2020 still favors SAVR in patients under 65 partly on conduction and durability grounds, and CONNAVIPRO is exactly the kind of data that keeps the U.S. age threshold conservative. Contemporary SAVR series in low-risk patients show meaningfully lower new-LBBB and third-degree AV block rates — except in bicuspid anatomy — and new-onset LBBB after SAVR carries an independent mortality signal (HR 1.60, per recent Annals of Thoracic Surgery data). For a 68-year-old with tricuspid anatomy — in ESC 2025's "SAVR preferred if low risk" zone but ACC/AHA 2020's "shared decision" zone — a one-in-five PPI risk with a self-expanding valve is not a rounding error.
Two other TAVR reports round out the day. A JACC Case Reports letter details snare-assisted transseptal antegrade TAVR in an 81-year-old with porcelain aorta and prohibitive surgical risk — a workable bailout when transfemoral access is unavailable. And a Japanese single-center series (N=767, 73 transaortic) found right mini-thoracotomy transaortic TAVR delivered equivalent 2-year survival to transfemoral despite higher-risk anatomy — useful alternative-access data, though single-center and retrospective limits generalizability.
Mitral Valve (MitraClip, PASCAL, TMVR)
M-TEER is the durable option for elderly mitral patients; TMVR is not yet a surgical substitute. A Future Cardiology review pulls TRAMI and EXPAND registry data on patients ≥75 and reports M-TEER 30-day mortality of 2-3% with stroke under 1% — numbers that justify ESC 2025's Class I posture for ventricular secondary MR meeting COAPT criteria, and align with ACC/AHA 2020's Class IIa for primary MR at high surgical risk. The more sobering figure is TMVR: 1-year mortality of 7-17% in early transfemoral/transseptal series and up to 29% after transapical TMVR. Neither guideline offers a Class I recommendation for TMVR, and this review reinforces why. Surgical repair — guideline-preferred and durable — remains the reference for primary MR in operable patients regardless of age. ESC 2025's upgrade of asymptomatic primary MR repair to Class I (with ≥3 of AF, SPAP >50 mmHg, LAVI ≥60 mL/m², ≥moderate TR) means more elderly patients reach a surgical trigger before they reach a transcatheter one. The elderly-MR decision tree runs surgery → M-TEER → TMVR only if M-TEER is anatomically unsuitable — not the reverse.
Tricuspid Valve (TriClip, TTVR)
The EVOQUE footprint keeps expanding into community programs. St. Joseph's Health in New Jersey added EVOQUE — the first FDA-approved transcatheter tricuspid replacement — to its cardiac program. Adoption pace matters because ESC 2025 rates transcatheter tricuspid treatment Class IIa (LOE A) for high-risk symptomatic severe TR based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 doesn't address transcatheter TR therapy at all. That gap between the U.S. guideline and the U.S. market is where regional programs are moving fastest. Real-world STS/ACC TVT Registry data on 1,034 TTVR procedures show 98.4% implant success, 3.1% 30-day mortality, and 15.9% new-CIED implantation — the last figure is the honest cost of tricuspid replacement and a reason the surgical alternative is not off the table for younger, operable patients. ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I (from ACC/AHA 2020's Class IIa), and contemporary cohorts with earlier referral show meaningful improvement over historical isolated TV surgery mortality of 8-20%. Separately, VDyne's TRIVITA pivotal trial (NCT07516444, N=730) is now recruiting head-to-head against EVOQUE — the first intra-class TTVR comparison the field will see.
Surgical vs. Transcatheter Comparisons
No head-to-head SAVR-vs-TAVR data today. The CONNAVIPRO PPI signal is the operative comparator: a 23.2% pacemaker rate with Navitor and 17.6% with Evolut PRO+ sits against contemporary SAVR series in low-risk populations where conduction complication rates are meaningfully lower except in bicuspid anatomy, and where LBBB post-SAVR carries an independent mortality signal (HR 1.60, Annals of Thoracic Surgery). For a 68-year-old with tricuspid anatomy — in ESC 2025's "SAVR preferred if low risk" zone and ACC/AHA 2020's "shared decision" zone — a one-in-five PPI risk with a self-expanding valve is the durability discussion by another name.
Preprint Highlights
[NOTABLE] WATCH-SHD prospectively validated a noise-adapted AI-ECG model on 596 outpatient echo-lab attendees using 30-second single-lead Apple Watch tracings; severe structural heart disease (LVEF <40%, severe left-sided valvular disease, or severe LVH) was present in 5.1%. AUROC 0.841, sensitivity 76.7%, NPV 98.5%, and a >60% reduction in number-needed-to-test versus usual care. Single-center, moderate sample, and PPV only 19.7% — this is not a screening deployment yet — but it is the first prospective external validation of a consumer-wearable structural heart disease screen and directly addresses the "who has undiagnosed severe AS in the community" question that early-intervention data (EARLY TAVR, RECOVERY) has made urgent.
Device & Technology
A CT-based one-click pipeline for regional quantification of aortic valve fibrocalcific degeneration was validated on 25 severe-AS patients, producing Dice coefficients of 0.86-0.89 versus expert manual analysis and completing in ≤2.5 minutes per case (Annals of Biomedical Engineering). Small sample, but the regional heterogeneity mapping is the interesting piece — it maps directly onto the ESC 2025 emphasis on lifetime management, where anatomic detail at the index procedure (calcium distribution, LVOT calcification, sinus geometry) determines future valve-in-valve feasibility. Automation of that read is a workflow story worth watching.
Industry & Market
Institutional flow into Edwards is the market story. Deutsche Bank ($516.55M), OneDigital, Nippon Life ($4.67M), and Oppenheimer all disclosed new or expanded EW positions. The clinical read-through: EARLY TAVR pushing early intervention in asymptomatic severe AS into ESC 2025 Class IIa territory expands the addressable SAPIEN market by an order of magnitude that Medtronic's Evolut franchise can't fully match if CONNAVIPRO's PPI signal holds up in prospective data.
Financial Analysis
Edwards' 6-month move from ~$79 to ~$93 tracks two concurrent catalysts: EARLY TAVR trial data reinforcing the asymptomatic-AS expansion thesis, and TRISCEND II supporting the EVOQUE tricuspid buildout — the latter now landing in community programs like St. Joseph's. Medtronic remains the volume-share leader in TAVR but carries the CONNAVIPRO overhang; the September 1 earnings call is the near-term test. Boston Scientific's 6-month drawdown (~$76 to ~$51) reflects broader medtech multiple compression more than valve-specific news — Watchman remains the dominant BSX structural heart story, not TAVR. Abbott's recovery to ~$111 reflects MitraClip's Class I upgrade in the ESC 2025 ventricular SMR pathway, even as CONNAVIPRO exposes the Navitor PPI cost.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Latest close: ~$92.56 | 5-day range $91.48-$93.91 | 6-month range $76.49-$96.29
- Market cap: $52.3B | P/E trailing 54.7 | P/E forward 26.9 | Beta 0.85
- Analyst target: $100.96 (26 analysts, range $84-$110); consensus: buy
- Next earnings: October 29, 2026 — EPS est $0.74, revenue est $1.68B
- Commentary: Institutional accumulation over the past week (Deutsche Bank, Oppenheimer, Nippon Life, OneDigital) is consistent with the SAPIEN + EVOQUE dual-franchise thesis. EARLY TAVR data expanding asymptomatic AS indications and the TRISCEND II tricuspid pathway remain the primary re-rating drivers. Valuation is stretched at 55x trailing but the forward multiple of 27x reflects TAM expansion, not just growth.
Medtronic (MDT)
- Latest close: ~$90.58 | 5-day range $88.50-$91.99 | 6-month range $72.65-$97.30
- P/E trailing: 24.3 | P/E forward 14.1 | Beta 0.57
- Analyst target: $98.44 (25 analysts, range $78-$121); consensus: buy
- Next earnings: September 1, 2026 — EPS est $1.39, revenue est $9.